Oncobiologics and IPCA create biosimilars alliance

Biosimilares/Novedades | Posted 13/06/2014 post-comment0

US-based Oncobiologics announced on 2 June 2014 the creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibodies with Indian generics maker IPCA Labs (IPCA).

Conference V14A17

Under the first part of the agreement, IPCA will in-license and commercialize biosimilars for India and associated markets. These products will be developed by Oncobiologics to US Food and Drug Administration (FDA) and European Union regulatory standards for global commercialization.

In the second part, Oncobiologics will replicate its biologicals R & D and manufacturing facility in India to create a world-class capability for IPCA for further biosimilar commercialization. Oncobiologics expects the R & D facility, which will be designed for the development and commercialization of complex monoclonal antibodies, to be operational in 2015 and the manufacturing facility to be operational by 2016.

Although the biosimilars in question are not mentioned, Oncobiologics states in its press release that they ‘are among the most popular therapies in the world for immunology and oncology disease indications’. These are likely to include biosimilars of Roche’s cancer and arthritis treatments Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan (rituximab), Eli Lilly’s cancer drug Erbitux (cetuximab) and Abbott’s arthritis treatment Humira (adalimumab), all of which are ‘in the pipeline’ according to the website of Oncobiologics.

Oncobiologics also made biosimilars agreements in 2013 with Viropro and Zhejiang Huahai Pharmaceutical for the development, manufacture and commercialization of several biosimilar monoclonal antibodies [1, 2].

Oncobiologics expects this latest partnership to launch its first biosimilar in 2017.

References

1. GaBI Online - Generics and Biosimilars Initiative. Oncobiologics and Viropro make biosimilar deal [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 13]. Available from: www.gabionline.net/Biosimilars/News/Oncobiologics-and-Viropro-make-biosimilar-deal

2. GaBI Online - Generics and Biosimilars Initiative. Huahai and Oncobiologics make biosimilars deal [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 13]. Available from: www.gabionline.net/Biosimilars/News/Huahai-and-Oncobiologics-make-biosimilars-deal

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Related content
Canada approves rituximab biosimilar Riabni
Rituxan V13C29
Biosimilares/Novedades Posted 09/07/2021
Canada approves pegfilgrastim biosimilar Nyvepria
Health Canada V13I20
Biosimilares/Novedades Posted 02/07/2021
FDA accepts application for Lupin’s pegfilgrastim biosimilar
Application V15a16
Biosimilares/Novedades Posted 21/06/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010